Peter Verdult

Stock Analyst at Citigroup

(n/a)

# 4,322

Out of 4,670 analysts

4

Total ratings

n/a

Success rate

-32.22%

Average return

Main Sectors:

Top Industries:

Drug Manufacturers - General Drug Manufacturers - Specialty & Generic Biotechnology

Stocks Rated by Peter Verdult

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	LLY Eli Lilly	Maintains: Buy	$1,060 → $1,250	$748.01	+67.11%	2	Oct 25, 2024
	EVO Evotec SE	Upgrades: Buy	n/a	$4.49	-	1	Jun 8, 2023
	GLPG Galapagos NV	Upgrades: Buy	n/a	$27.13	-	1	Jan 27, 2022

Eli Lilly

Oct 25, 2024

Maintains: Buy

Price Target: $1,060 → $1,250

Current: $748.01

Upside: +67.11%

Evotec SE

Jun 8, 2023

Upgrades: Buy

Price Target: n/a

Current: $4.49

Upside: -

Galapagos NV

Jan 27, 2022

Upgrades: Buy

Price Target: n/a

Current: $27.13

Upside: -